An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs Itacitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Incyte Corporation
- 02 Feb 2018 Planned number of patients changed from 57 to 60.
- 14 Jul 2017 Planned number of patients changed from 48 to 57.
- 01 Nov 2016 Status changed from not yet recruiting to recruiting.